Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBX-1400 for Severe Combined Immunodeficiency
NCT02860559Phase 1Unknown
- Sponsor
- Taiga Biotechnologies, Inc.
- Start
- Aug 2021
- Primary completion
- Feb 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TBX-1400 in severe combined immunodeficiency (SCID), sponsored by Taiga Biotechnologies, Inc. Primary endpoint: Adverse Events following transplant with TBX-1400 at 2 years. Status: unknown.
02
Drugs
TBX-1400
03
Conditions
severe combined immunodeficiency (SCID)
Beyond the preview
Go deeper on NCT02860559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02860559.